Clinical relevance of thyroid-stimulating immunoglobulin as a biomarker of the activity of thyroid eye disease. 2023

Hansol Jeon, and Joo Yeon Lee, and Yu Jeong Kim, and Min Joung Lee
Department of Ophthalmology, Hallym University Sacred Heart Hospital, Anyang, Korea.

Although it has been reported that thyroid-stimulating immunoglobulin (TSI) is associated with the clinical characteristics of thyroid eye disease (TED), there is a paucity of literature regarding the role of TSI in diagnosing active TED. This study investigated the relationship between the level of TSI and the activity of TED and assessed the cut-off value of TSI discriminating active TED from inactive TED. This cross-sectional study included 101 patients with TED. TSI was quantitatively measured with a cell-based bioassay using a chimeric TSH receptor and a cyclic adenosine monophosphate response element-dependent luciferase. The association between TSI and a variety of demographic and clinical features of TED was analysed. Multivariate regression analysis was performed to determine possible independent factors affecting the level of TSI. TSI level was higher in males than in females (p = 0.023) and smokers than in nonsmokers (p = 0.004). TSI level was inversely correlated with the duration of ocular symptoms (r = -0.295, p = 0.003). The level of TSI was also significantly different when compared to the thyroid function (p = 0.003), TED activity (p < 0.001), and TED severity (p = 0.001). Multivariate regression analysis revealed a significant relationship between TED activity and thyroid function jointly and the TSI level. The cut-off level of TSI for predicting active TED was a specimen-to-reference ratio of 406.7 (p < 0.001, area under the curve = 0.847, sensitivity 77.4%, specificity 81.3%). TSI was a functional biomarker strongly associated with TED activity even after being adjusted by other clinical characteristics. Serum TSI level may help identify patients with active TED in clinics.

UI MeSH Term Description Entries
D008297 Male Males
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000092522 Clinical Relevance Criteria to determine whether a finding (e.g., clinical examination, lab test, imaging results) requires a medical intervention for meaningful improvement in outcome often to avoid OVERDIAGNOSIS and/or OVERTREATMENT. Clinical Importance,Clinical Significance,Importance, Clinical,Relevance, Clinical,Significance, Clinical
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D049970 Graves Ophthalmopathy An autoimmune disorder of the EYE, occurring in patients with Graves disease. Subtypes include congestive (inflammation of the orbital connective tissue), myopathic (swelling and dysfunction of the extraocular muscles), and mixed congestive-myopathic ophthalmopathy. Graves Eye Disease,Ophthalmopathy, Infiltrative,Ophthalmopathy, Thyroid-Associated,Thyroid Eye Disease,Thyroid-Associated Ophthalmopathy,Congestive Ophthalmopathy,Dysthyroid Ophthalmopathy,Edematous Ophthalmopathy,Graves Orbitopathy,Myopathic Ophthalmopathy,Ophthalmopathies, Thyroid-Associated,Thyroid-Associated Ophthalmopathies,Congestive Ophthalmopathies,Disease, Graves Eye,Disease, Thyroid Eye,Dysthyroid Ophthalmopathies,Edematous Ophthalmopathies,Eye Disease, Graves,Eye Disease, Thyroid,Infiltrative Ophthalmopathies,Infiltrative Ophthalmopathy,Myopathic Ophthalmopathies,Ophthalmopathy, Congestive,Ophthalmopathy, Dysthyroid,Ophthalmopathy, Edematous,Ophthalmopathy, Graves,Ophthalmopathy, Myopathic,Ophthalmopathy, Thyroid Associated,Orbitopathy, Graves,Thyroid Associated Ophthalmopathies,Thyroid Associated Ophthalmopathy,Thyroid Eye Diseases
D018828 Immunoglobulins, Thyroid-Stimulating Autoantibodies that bind to the thyroid-stimulating hormone (TSH) receptor (RECEPTORS, THYROTROPIN) on thyroid epithelial cells. The autoantibodies mimic TSH causing an unregulated production of thyroid hormones characteristic of GRAVES DISEASE. Antibodies, Thyroid-Stimulating,Ig Thyroid Stimulating,Thyroid-Stimulating Antibodies,Thyroid-Stimulating Autoantibodies,Thyroid-Stimulating Autoantibody,Thyroid-Stimulating Immunoglobulins,Immunoglobulin, Thyroid-Stimulating,Thyroid Stimulating Antibody,Thyroid-Stimulating Immunoglobulin,Antibody, Thyroid Stimulating,Autoantibody, Thyroid-Stimulating,Immunoglobulin, Thyroid Stimulating,Stimulating Antibody, Thyroid,Thyroid Stimulating Antibodies,Thyroid Stimulating Autoantibodies,Thyroid Stimulating Autoantibody,Thyroid Stimulating Immunoglobulin,Thyroid Stimulating Immunoglobulins,Thyroid Stimulating, Ig

Related Publications

Hansol Jeon, and Joo Yeon Lee, and Yu Jeong Kim, and Min Joung Lee
June 2022, BMJ open,
Hansol Jeon, and Joo Yeon Lee, and Yu Jeong Kim, and Min Joung Lee
June 2024, European thyroid journal,
Hansol Jeon, and Joo Yeon Lee, and Yu Jeong Kim, and Min Joung Lee
January 2023, Scientific reports,
Hansol Jeon, and Joo Yeon Lee, and Yu Jeong Kim, and Min Joung Lee
January 2006, Ophthalmic plastic and reconstructive surgery,
Hansol Jeon, and Joo Yeon Lee, and Yu Jeong Kim, and Min Joung Lee
June 1981, Australian and New Zealand journal of medicine,
Hansol Jeon, and Joo Yeon Lee, and Yu Jeong Kim, and Min Joung Lee
May 2014, The Journal of clinical endocrinology and metabolism,
Hansol Jeon, and Joo Yeon Lee, and Yu Jeong Kim, and Min Joung Lee
April 1976, The Journal of clinical endocrinology and metabolism,
Hansol Jeon, and Joo Yeon Lee, and Yu Jeong Kim, and Min Joung Lee
December 1998, Endocrine journal,
Hansol Jeon, and Joo Yeon Lee, and Yu Jeong Kim, and Min Joung Lee
January 2018, Ophthalmic plastic and reconstructive surgery,
Hansol Jeon, and Joo Yeon Lee, and Yu Jeong Kim, and Min Joung Lee
September 2017, Clinical and experimental immunology,
Copied contents to your clipboard!